Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Opicapone on Levodopa Pharmacokinetics in Healthy Subjects
NCT02169414Phase 1Completed
- Sponsor
- BIAL
- Start
- Feb 2010
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration of Levodopa at 24 hours, Time to Reach Maximum Plasma Concentration of Levodopa at 24 hours and 2 more. Started Feb 2010; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02169414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169414.